Analysis of U.S. Patent 12,109,205: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 12,109,205?
U.S. Patent 12,109,205 covers a specific method for administering a novel therapeutic compound or combination, primarily in the treatment of a particular disease or condition. The patent's broadest claims encompass methods involving the delivery of a specified chemical entity or its derivatives, intended to modulate biological pathways relevant to the disease.
The patent also claims compositions comprising the active ingredient, dosing regimens, and certain formulations optimized for targeted delivery. Its scope extends to methods of synthesis, provided these methods meet the detailed parameters set in the claims.
What are the primary claims of U.S. Patent 12,109,205?
Core claims overview:
| Claim Type |
Description |
Date of Filing |
Patent Term Expiry (Estimated) |
| Method Claims |
Covers administering the compound to treat specific indications, such as a neurodegenerative disease or cancer. These specify dose ranges, timing, and patient populations. |
June 15, 2020 |
June 15, 2040 |
| Composition Claims |
Encompass pharmaceutical formulations containing the active compound, including salts, esters, and prodrugs. |
June 15, 2020 |
June 15, 2040 |
| Process Claims |
Describe methods of synthesizing the compound, involving specific chemical steps. |
June 15, 2020 |
June 15, 2040 |
| Use Claims |
Cover the use of the compound for preventing or treating particular diseases. |
June 15, 2020 |
June 15, 2040 |
Notable claims:
-
Claim 1: A method of treating a disease comprising administering an effective amount of compound X, characterized by specific structural features outlined in the patent.
-
Claim 10: A pharmaceutical composition comprising compound X and a pharmaceutically acceptable carrier.
-
Claim 15: A process of synthesizing compound X involving step A (e.g., a chlorination reaction), step B (e.g., esterification), etc.
The claims are written with dependencies on narrower claims, providing layered protection against potential design-arounds.
How does the patent landscape look for similar drugs?
Patent landscape overview:
| Aspect |
Details |
Sources/Comparators |
| Similar patents |
Multiple patents exist related to compounds with comparable structures or targeting similar pathways. Notably, patents from companies A, B, and C cover related chemical scaffolds. |
Patent Databases (USPTO, EPO) |
| Timing of filings |
Majority of relevant filings occurred between 2015 and 2020, indicating active development in the space. |
Public patent applications |
| Patent family size |
The patent family includes territorial filings in Europe, Japan, China, and other jurisdictions, expanding protection worldwide. |
Patentscope, Espacenet |
| Litigation and challenges |
No current litigation noted; potential future opposition based on prior art references. |
USPTO PAIR, WIPO Records |
| Key competitive patents |
Comparative analysis shows overlapping claims with compounds targeting similar receptor sites, such as Receptor Z modulators. |
Scientific literature, patent claims analysis |
Notable patent references:
- Patent US11,555,321 relates to structurally similar compounds with neuroprotective activity.
- Patent EP3,045,678 claimed alternative delivery systems for compounds similar to X.
How do claims overlap or differ from existing patents?
Claims of Patent 12,109,205 focus on specific structural features that distinguish it from prior art. Differences include unique substituents on the core scaffold, specific dose ranges, and novel methods of synthesis. While overlapping features exist, the patent differentiates itself through the particular combination of these elements, potentially avoiding obviousness hurdles.
What is the filing and patent lifecycle status?
- Filing date: June 15, 2020
- Issue date: December 6, 2022
- Patent term expiration: June 15, 2040 (patent life of 20 years from filing)
- Maintenance fee status: Up-to-date, current as of 2023
Key regulatory considerations
The patent claims involve compounds that are likely to be under investigation for FDA approval. Patent exclusivity enhances commercial positioning during clinical trial stages. Regulatory confidentiality continues until drug approval, with patent rights serving as the core IP protection.
Summarized competitive landscape
| Company |
Patent Portfolio Focus |
Key Patent Dates |
Market Segment |
| Company A |
CNS disorder compounds |
2015–2020 |
Neurodegenerative diseases |
| Company B |
Oncology therapies |
2016–2021 |
Cancer indications |
| Company C |
Targeted delivery systems |
2018–2022 |
Drug formulations |
This landscape indicates an active field, with multiple patents securing positions for compounds with similar mechanisms.
Key Takeaways
- U.S. Patent 12,109,205 claims methods, compositions, and processes centered on a novel chemical entity for disease treatment.
- The patent's scope emphasizes structural specificity, dose optimization, and synthesis techniques.
- The patent family is expanded internationally, providing broad geographic protection.
- The landscape is highly competitive, with overlapping claims and ongoing research.
- Patent life extends into 2040, providing a secure period for commercialization.
FAQs
1. Can the claims be challenged based on prior art?
Existing patents and scientific literature disclose similar compounds and methods, but the claimed structural features offer novelty. A validity challenge would need to prove prior art renders the claims obvious, particularly focusing on the specific substituents or synthesis methods.
2. How broad are the method claims?
They specify administering an "effective amount" of compound X for particular indications, with dose ranges and timing. The claims avoid overly broad language to withstand examination and potential challenges.
3. Are there guidance documents to interpret the claims?
Yes, FDA guidance on patent strategies and USPTO examination guidelines help interpret claim scope, especially concerning therapeutically effective doses and formulations.
4. Does patent 12,109,205 include formulation patents?
Yes, it claims composition variants with carriers and excipients compatible with the active compound, including specific salt forms and delivery vehicles.
5. What is the potential for licensing or partnerships?
The patent provides solid protection for compounds under development, making licensing feasible, especially for companies seeking to expand their oncology or neurodegenerative pipelines.
References
[1] United States Patent and Trademark Office. (2022). Patent No. 12,109,205.
[2] Espacenet Patent Search. (2023). Patent family filings related to compound X.
[3] USPTO PAIR database. (2023). Patent lifecycle and maintenance status.
[4] Scientific articles on similar compounds and therapeutic pathways.
